Inmune Bio Inc

Inmune Bio Inc. is poised to unveil top-line data from its Phase 2 MINDFuL trial in early Alzheimer’s Disease on June 30, 2025, with the company’s shares experiencing a 72% surge in pre-market trading ahead of the announcement.

Inmune Bio Inc., a clinical-stage biotech company, is focused on developing innovative cancer treatments and advancing its mission to bring new therapeutic options to patients.

Inmune Bio Inc, a clinical-stage biotech firm, faces significant financial and market challenges as it strives to develop groundbreaking cancer treatments, presenting a high-risk, high-reward scenario for investors.

Inmune Bio Inc, a clinical-stage biotech company, is at a critical juncture as it navigates the challenges of developing cancer treatments, with its financial performance and competitive landscape raising questions about its long-term success.

Inmune Bio Inc. is a clinical-stage biotech company dedicated to developing innovative cancer treatments, offering hope to patients and families affected by the disease.

Inmune Bio Inc. reported its first quarter 2025 results, with a focus on advancing its pipeline of cancer therapies and a market capitalization of approximately $173.53 million.

Inmune Bio Inc. is set to release its Q1 2025 earnings, a critical moment for the biotech company as investors and stakeholders await signs of progress in its pipeline and potential for market success.